VivoSeq
Immunology

Ulcerative Colitis

387

Pipeline Programs↗

160

Active Trials↗

127

Companies Involved↗

Ulcerative Colitis is a highly competitive landscape with 387 programs across 127 companies. The most active players are Theravance Biopharma, Seres Therapeutics, Inc., Bridge Biotherapeutics, Inc.. 41 therapies are approved with 64 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

92/100

Pipeline Velocity

65/100

Mech. Concentration

10/100

Completion Rate

73/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Theravance Biopharma

2 programs

Phase 1S

Seres Therapeutics, Inc.

2 programs

Phase 1B

Bridge Biotherapeutics, Inc.

1 program

Phase 1T

Telsar Pharma Inc.

1 program

Phase 1T

Topivert Pharma Ltd

1 program

Phase 1H

Hebei Senlang Biotechnology Inc., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical34

Golimumab

Johnson & Johnson

Infliximab

Organon and Co

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Methylprednisolone Sodium Succinate

Massachusetts Eye and Ear Infirmary

Mebendazole

Wim Janssens

Phase 168

Hydroxychloroquine

Alnylam Pharmaceuticals

Aldesleukin

Iovance Biotherapeutics, Inc.

RG6026

Roche

Caffeine

Hikma Pharmaceuticals LLC

Midazolam

Conrado Roberto Hoffmann Filho

Phase 2180

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Certolizumab Pegol

UCB

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Itacitinib

Incyte

Melatonin

Neurim Pharmaceuticals Ltd.

Phase 364

Mirikizumab

Eli Lilly

Etrasimod

Pfizer

Filgotinib

Gilead

Guselkumab

Johnson & Johnson

Risankizumab

AbbVie

Approved41

Amoxicillin

Global Antibiotics Research and Development Partnership

Sulfasalazine

Pfizer

Mesalamine

Takeda

Azathioprine

Legacy Health System

Cyclosporine

Novartis

Analysis

Modality Breakdown

88%

Small molecule

351 of 401 classified programs — the dominant modality here.

12%ALL OTHERSMonoclonal antibody379%Cell therapy61%Protein / enzyme4<1%Peptide1<1%RNA therapy1<1%Vaccine1<1%

Small molecule leads; the ring shows all 401 classified programs, each share of the total. Modality classified for 98% of 461 pipeline programs.

Analysis

Trial Status

678

clinical trials

Completed337 · 50%
Terminated99 · 15%
Recruiting89 · 13%
Unknown status54 · 8%
Active, not recruiting40 · 6%
Not yet recruiting29 · 4%
Other30 · 4%

Clinical Trials

Trial Activity

678 trials

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Recruiting·Takeda logoTakeda·Phase 3·NCT06100289·70 enrolled
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
Recruiting·MMedical University of Lodz·Phase 2·NCT06453317·172 enrolled
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting·Takeda logoTakeda·Phase 2·NCT06254950·207 enrolled
Oral Vitamin D3 Effect on Inflammatory Biomarkers in Ulcerative Colitis Patients
Recruiting·—·N/A·NCT07269223·60 enrolled
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06651281·1,380 enrolled
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Recruiting·Takeda logoTakeda·Phase 3·NCT05442567·240 enrolled
Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
Recruiting·TTanta University·N/A·NCT06335160·46 enrolled
Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·N/A·NCT07442045·150 enrolled
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Recruiting·TTanta University·Phase 2·NCT05575505·44 enrolled
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2/3·NCT05076175·120 enrolled
Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
Recruiting·BBiocad·Phase 2·NCT07080034·198 enrolled
Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis
Recruiting·—·Phase 4·NCT07258771·110 enrolled
Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
Recruiting·—·Phase 4·NCT05867329·162 enrolled
Rupatadine in Patients With Ulcerative Colitis
Recruiting·—·Phase 2·NCT07064707·60 enrolled
Desloratadine in Patients With Ulcerative Colitis
Recruiting·TTanta University·Phase 2·NCT07333716·44 enrolled
Page 1 of 46

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)